Shanghai Henlius Biotech (HKG:2696) dosed the first patient in the third stage of a phase 2/3 clinical trial of Hansizhuang in combination with bevacizumab injection and chemotherapy in Japan, a Thursday bourse filing said.
The drug is indicated for the first-line treatment of metastatic colorectal cancer.
A phase 3 study of the drug is also ongoing in mainland China and Indonesia.
Price (HKD): $21.70, Change: $-0.20, Percent Change: -0.91%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。